Brief: Transgene Anticipates Significant Progress From Immunotherapy Pipeline In 2024
March 27 (Reuters) - Transgene SA TRNG.PA :
* TRANSGENE ANTICIPATES SIGNIFICANT PROGRESS FROM
IMMUNOTHERAPY
PIPELINE IN 2024
* EXTENDS FINANCIAL VISIBILITY UNTIL Q4 2025
Source text for Workspace: ID:nGNE6dCmqf
Further company coverage: TRNG.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Transgene SA
See all newsFrance's Transgene H1 operating income falls on lower tax credit
Transgene jumps 20% on positive cancer vaccine data in early trial
Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
France's Transgene 2025 net loss widens on higher financial costs